GlassScriptPhysician profile
Madhavi Siddhanthi
NPI 1659543130
$5,093.02
in general payments reported to CMS, 2019-2025
28 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $253 · 2021: $212 · 2022: $485 · 2023: $832 · 2024: $1,477 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,606 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,606.37 |
| Education | $119.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,107.94 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Janssen Biotech, INC. | $668.86 | 2022-2025 | Tremfya, Remicade, Stelara |
| Abbvie INC. | $496.84 | 2019-2025 | Skyrizi, Rinvoq |
| Mallinckrodt Hospital Products INC. | $342.26 | 2022-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $340.69 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $271.07 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $257.15 | 2023-2025 | Saphnelo |
| Pfizer INC. | $250.62 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $230.62 | 2021-2025 | Lupkynis |
| Ucb, INC. | $213.12 | 2023-2025 | Bimzelx, Cimzia |
| Horizon Therapeutics Plc | $117.50 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $101.73 | 2019-2025 | Taltz, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.70 | 2019-2024 | Cyltezo |
| Glaxosmithkline, LLC. | $85.42 | 2019-2024 | Benlysta |
| Actelion Pharmaceuticals US, INC. | $70.93 | 2023-2025 | Opsumit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $69.89 | 2024-2025 | |
| Genzyme Corporation | $60.11 | 2024-2025 | |
| Radius Health, INC. | $56.48 | 2024 | Tymlos |
| Organon LLC | $46.20 | 2024 | |
| Octapharma USA, INC. | $36.83 | 2023-2024 | Octagam Immune Globulin (Human) |
| Invivyd INC | $26.72 | 2025 | Pemgarda |
| Antares Pharma, INC. | $25.44 | 2019-2020 | |
| Medexus Pharma, INC. | $24.34 | 2019-2020 | |
| Kyowa Kirin, INC. | $23.78 | 2025 | |
| Ferring Pharmaceuticals INC. | $21.66 | 2022 | |
| Genentech USA, INC. | $16.22 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $15.71 | 2024 | Arcalyst |
| Sandoz INC. | $15.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madhavi Siddhanthi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.